JP2017534256A5 - - Google Patents

Info

Publication number

JP2017534256A5

JP2017534256A5 JP2017513781A JP2017513781A JP2017534256A5 JP 2017534256 A5 JP2017534256 A5 JP 2017534256A5 JP 2017513781 A JP2017513781 A JP 2017513781A JP 2017513781 A JP2017513781 A JP 2017513781A JP 2017534256 A5 JP2017534256 A5 JP 2017534256A5

Authority

JP

Japan

Prior art keywords

seq

antibody

amino acid

cll

hvr

Prior art date

2015-09-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 29
• 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 18
• 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 18
• 210000004027 cell Anatomy 0.000 claims 12
• 239000003814 drug Substances 0.000 claims 10
• 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims 7
• 206010028980 Neoplasm Diseases 0.000 claims 7
• 102000050908 human CLEC12A Human genes 0.000 claims 7
• 239000008194 pharmaceutical composition Substances 0.000 claims 7
• 201000011510 cancer Diseases 0.000 claims 6
• 229940124597 therapeutic agent Drugs 0.000 claims 6
• 238000000034 method Methods 0.000 claims 5
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
• 125000005843 halogen group Chemical group 0.000 claims 4
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 3
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 3
• 241000282567 Macaca fascicularis Species 0.000 claims 3
• 235000001014 amino acid Nutrition 0.000 claims 3
• 150000001413 amino acids Chemical class 0.000 claims 3
• 229960002756 azacitidine Drugs 0.000 claims 3
• 238000010276 construction Methods 0.000 claims 3
• 229940127121 immunoconjugate Drugs 0.000 claims 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
• 239000012664 BCL-2-inhibitor Substances 0.000 claims 2
• 229940123711 Bcl2 inhibitor Drugs 0.000 claims 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
• 125000003118 aryl group Chemical group 0.000 claims 2
• 239000012472 biological sample Substances 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 239000002254 cytotoxic agent Substances 0.000 claims 2
• 229960003603 decitabine Drugs 0.000 claims 2
• 238000000338 in vitro Methods 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 2
• CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical class C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 239000000523 sample Substances 0.000 claims 2
• 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
• 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
• 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 241000283080 Proboscidea <mammal> Species 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 claims 1
• 125000002947 alkylene group Chemical group 0.000 claims 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
• 229930195731 calicheamicin Natural products 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 230000004663 cell proliferation Effects 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 238000004581 coalescence Methods 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 231100000599 cytotoxic agent Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 125000005842 heteroatom Chemical group 0.000 claims 1
• 125000000623 heterocyclic group Chemical group 0.000 claims 1
• TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims 1
• 230000036039 immunity Effects 0.000 claims 1
• 125000005647 linker group Chemical group 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000002184 metal Substances 0.000 claims 1
• 230000035772 mutation Effects 0.000 claims 1
• 229910052757 nitrogen Inorganic materials 0.000 claims 1
• 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1